

# William Y Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1399856/publications.pdf>

Version: 2024-02-01

64  
papers

9,486  
citations

94269

37  
h-index

114278

63  
g-index

67  
all docs

67  
docs citations

67  
times ranked

14291  
citing authors

#	ARTICLE	IF	CITATIONS
1	PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner. <i>Cancer Immunology Research</i> , 2022, 10, 285-290.	1.6	13
2	A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response. <i>Cell Reports Medicine</i> , 2022, 3, 100602.	3.3	1
3	Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4599-4609.	3.2	26
4	Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. <i>British Journal of Cancer</i> , 2021, 125, 1251-1260.	2.9	77
5	Entinostat induces antitumor immune responses through immune editing of tumor neoantigens. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	43
6	Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 1536.	3.4	28
7	Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3140-3148.	0.8	72
8	Pparg signaling controls bladder cancer subtype and immune exclusion. <i>Nature Communications</i> , 2021, 12, 6160.	5.8	28
9	ZHX2 promotes HIF1 $\alpha$ oncogenic signaling in triple-negative breast cancer. <i>ELife</i> , 2021, 10, .	2.8	21
10	RAF1 amplification: an exemplar of MAPK pathway activation in urothelial carcinoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	6
11	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 420-433.	0.9	741
12	RNA Expression Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder Reveals a Basal-Like Molecular Subtype. <i>American Journal of Pathology</i> , 2020, 190, 134-144.	1.9	13
13	Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss. <i>Molecular Cell</i> , 2020, 77, 1294-1306.e5.	4.5	41
14	Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). <i>Clinical Genitourinary Cancer</i> , 2020, 18, 378-386.e1.	0.9	15
15	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. <i>Eur Urol</i> 2020;77:434-438. <i>European Urology</i> , 2020, 77, 436-438.	0.9	1
16	Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. <i>JCI Insight</i> , 2020, 5, .	2.3	11
17	MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression. <i>Nature Communications</i> , 2019, 10, 1515.	5.8	25
18	Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. <i>British Journal of Cancer</i> , 2018, 119, 801-807.	2.9	29

#	ARTICLE	IF	CITATIONS
19	Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy. <i>Cancer Research</i> , 2018, 78, 3954-3968.	0.4	82
20	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. <i>Science</i> , 2018, 361, 290-295.	6.0	134
21	Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. <i>Clinical Cancer Research</i> , 2018, 24, 5918-5924.	3.2	84
22	Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 4804-4820.	3.9	210
23	Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. <i>PLoS ONE</i> , 2018, 13, e0193832.	1.1	74
24	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 544-554.	0.9	638
25	MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma. <i>Nature Communications</i> , 2017, 8, 15770.	5.8	64
26	<i>Sav1</i> Loss Induces Senescence and Stat3 Activation Coinciding with Tubulointerstitial Fibrosis. <i>Molecular and Cellular Biology</i> , 2017, 37, .	1.1	29
27	Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer. <i>Cancer Causes and Control</i> , 2017, 28, 539-544.	0.8	14
28	Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors. <i>Cancer Research</i> , 2017, 77, 719-731.	0.4	169
29	Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era. <i>Cancer</i> , 2016, 122, 2988-2995.	2.0	32
30	Intrinsic Genomic Differences Between African American and White Patients With Clear Cell Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 664.	3.4	54
31	The Binding Site Barrier Elicited by Tumor-Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors. <i>ACS Nano</i> , 2016, 10, 9243-9258.	7.3	161
32	Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting. <i>Bladder Cancer</i> , 2016, 2, 37-47.	0.2	184
33	Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. <i>JCI Insight</i> , 2016, 1, e85902.	2.3	179
34	Coexistent ARID1A and PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. <i>Nature Communications</i> , 2015, 6, 6118.	5.8	247
35	Targeting Tumor Hypoxia With Hypoxia-Activated Prodrugs. <i>Journal of Clinical Oncology</i> , 2015, 33, 1505-1508.	0.8	41
36	Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 386.e1-386.e6.	0.8	15

#	ARTICLE	IF	CITATIONS
37	mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma. PLoS ONE, 2014, 9, e104413.	1.1	20
38	The Geriatrics and Genetics behind Bladder Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e192-e195.	1.8	3
39	Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database"UNC GOLD. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 32.e1-32.e9.	0.8	8
40	Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3110-3115.	3.3	736
41	Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. Journal of Clinical Investigation, 2014, 124, 553-563.	3.9	53
42	Stearoyl Co-A Desaturase 1 as a ccRCC Therapeutic Target: Death by Stress. Clinical Cancer Research, 2013, 19, 3111-3113.	3.2	12
43	HIF1 $\alpha$ and HIF2 $\alpha$ independently activate SRC to promote melanoma metastases. Journal of Clinical Investigation, 2013, 123, 2078-2093.	3.9	132
44	Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer. Cell, 2012, 149, 307-321.	13.5	637
45	State of the Science: An Update on Renal Cell Carcinoma. Molecular Cancer Research, 2012, 10, 859-880.	1.5	142
46	Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 608-613.	0.8	15
47	Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL. Journal of Cellular and Molecular Medicine, 2011, 15, 187-195.	1.6	76
48	Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors. Cancer Cell, 2010, 17, 547-559.	7.7	215
49	HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opinion on Therapeutic Targets, 2010, 14, 1047-1057.	1.5	63
50	Drug Efficacy Testing in Mice. Current Topics in Microbiology and Immunology, 2010, 355, 19-38.	0.7	14
51	Molecular responses to hypoxia: ancient pathways, clinical promises. Journal of Cellular and Molecular Medicine, 2009, 13, 2757-2758.	1.6	0
52	HIF2 $\alpha$ cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation, 2009, 119, 2160-2170.	3.9	129
53	VHL Inactivation: A New Road to Senescence. Cancer Cell, 2008, 13, 295-297.	7.7	8
54	mTOR pathway in renal cell carcinoma. Expert Review of Anticancer Therapy, 2008, 8, 283-292.	1.1	48

#	ARTICLE	IF	CITATIONS
55	VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail. <i>Molecular and Cellular Biology</i> , 2007, 27, 157-169.	1.1	230
56	pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF- $\kappa$ B Agonist Card9 by CK2. <i>Molecular Cell</i> , 2007, 28, 15-27.	4.5	163
57	The Regulation of INK4/ARF in Cancer and Aging. <i>Cell</i> , 2006, 127, 265-275.	13.5	885
58	Failure to prolyl hydroxylate hypoxia-inducible factor $\hat{\pm}$ phenocopies VHL inactivation in vivo. <i>EMBO Journal</i> , 2006, 25, 4650-4662.	3.5	210
59	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. <i>Cancer Cell</i> , 2006, 9, 485-495.	7.7	427
60	Molecular Pathways in Renal Cell Carcinomaâ€™ Rationale for Targeted Treatment. <i>Seminars in Oncology</i> , 2006, 33, 588-595.	0.8	62
61	Role of VHL Gene Mutation in Human Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 4991-5004.	0.8	874
62	The von Hippelâ€™Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. <i>Current Opinion in Genetics and Development</i> , 2003, 13, 55-60.	1.5	170
63	Inhibition of HIF2 $\hat{\pm}$ Is Sufficient to Suppress pVHL-Defective Tumor Growth. <i>PLoS Biology</i> , 2003, 1, e83.	2.6	516
64	Mouse Reporter Strain for Noninvasive Bioluminescent Imaging of Cells that have Undergone Cre-Mediated Recombination. <i>Molecular Imaging</i> , 2003, 2, 153535002003031.	0.7	36